Project Grant R01HL178475
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...
- This $229,608 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research investigating the role of pleural mesothelial cells in lung injury, repair, and regeneration. The award to Mayo Clinic aims to conduct lineage-tracing experiments in mouse models of lung injury and regeneration, and subsequent genomic analysis of the collected pleural mesothelial cells. This research seeks to improve the understanding of repair...
- This federal Project Grant award of $811,370.00, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to study the role of the Hippo-YAP/TAZ signaling pathway in regulating alveolar epithelial cell regeneration during lung repair. The research aims to determine the critical cellular and molecular mechanisms that facilitate normal alveolar repair and regeneration, with the overarching hypothesis that dynamic,...
- This Project Grant award of $618,450.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to identify key regulators of vascular homeostasis and understand how they maintain normal vascular function. The principal investigators at the Medical College of Wisconsin are focusing on understanding the role of the RNA-binding protein PABPC1 in suppressing endothelial cell activation and inflammation to prevent the loss of vascular...
- The University of Rochester was awarded a $226,101 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on pulmonary angioblasts and their role in vascular development. The project aims to leverage existing single-cell RNA sequencing data to uncover novel insights into the cellular characteristics and regulatory mechanisms governing pulmonary angioblasts, which are critical for vascular regeneration and the...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $701,795 to The Trustees of the University of Pennsylvania to conduct research aimed at defining the cardinal functions of lung progenitors during regeneration. The 4-year project, which began in September 2025, utilizes a multi-modal approach including cell lineage tracing, single-cell analysis, histological spatial analysis, and cross-species comparison to...
- This Project Grant award for $814,387 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research to investigate the role of a novel subpopulation of innate lymphoid cells (ILC3s) in lung infections and vascular regeneration. The award recipient, The Trustees of Columbia University, will utilize mouse models, single-cell analysis, and in vitro assays to: Define the tissue niche and response dynamics of lung vascular ILC3s (VILC3s),...
- This $721,826 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify molecular mechanisms regulating alveolar matrix fibroblast function and their role in supporting vascular capillary formation. The research is being conducted by Children's Hospital Medical Center in Cincinnati, Ohio to advance the understanding of alveolar septation and septal wall maturation, which is...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research into the role of post-transcriptional RNA modifications in lung development and regeneration. The $768,985 award, effective September 1, 2025 through June 30, 2029, will enable researchers at Columbia University's Health Sciences Division to study how the METTL3/14 complex-mediated RNA modifications, including on the SOX9 transcript, regulate lung...
- This federal Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research on mesenchymal cell plasticity and signaling in lung regeneration. The award aims to examine how specific mesenchymal cell lineages establish and maintain maladaptive epithelial regeneration after severe lung injury, such as from influenza or COVID-19. Key objectives include investigating the proliferation, plasticity, and Notch...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the mechanosensitive mechanisms underlying angiogenesis and lung regeneration. The $618,838 award to the Medical College of Wisconsin aims to investigate how mechanical stretching forces control angiogenesis during compensatory lung growth after pneumonectomy. The research will focus on the role of the focal adhesion protein paxillin in regulating angiogenic signaling pathways involving angiopoietins and the Tie2 receptor in alveolar epithelial cells and endothelial cells. This work is expected to provide insights into stimulating the regenerative capacity of the lungs, which could benefit patients with lung diseases. The project period runs from August 2025 to May 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $618.8k | 8/18/25 |